九州酷游(ku游)

Be the most trusted biotech company

2025-02-20

Global Second PD-L1 ADC: Henlius’ HLX43, a Novel PD-L1 ADC, Advances to Phase 2 Clinical Trials with First Patient Dosed
2021-11-18

Making biologic medicines more accessible

Global biopharmaceutical company Henlius aims to greatly improve patient well-being with affordable and innovative biologic medicines
2020-02-14

Shanghai Henlius CEO Wants To Capitalize On First-Mover Status

Generics Bulletin
2019-05-09

An original force in biosimilars

Nature Research
2018-06-27

Growing Antibody Industry in China Sees Major Opportunities

GEN Exclusives
2018-05-10

China's global investment push opens doors for domestic biotechs

BIOPHARMA DIVE